ACSL3

一句话亮点 这篇文章发现，PHB2通过结合并激活脂代谢酶ACSL3，促进单不饱和脂肪酸（MUFA）掺入膜磷脂，从而抑制铁死亡、驱动胃癌顺铂耐药；而FDA已批准的CXCR4拮抗剂Mavorixafor能打断这个蛋白-蛋白相互作用，将"耐药"的膜脂组成"拨回"易铁死亡状态，在体内模型里重新增敏顺铂。 背景/痛点 铂类是胃癌化疗的基石，但耐药几乎是宿命。经典机制——DNA修复增强、药物外排、凋亡逃逸——已经研究了很多年，但不足以解释临床耐药的顽固性。所以作者把视线投向非凋亡性细胞死亡，尤其铁死亡。铁死亡的关键在于膜脂上多不饱和脂肪酸（PUFA）被氧化，而单不饱和脂肪酸（MUFA）的掺入能"踩刹车"，减少脂质过氧化底物。ACSL4是PUFA激活酶，促铁死亡；ACSL3是MUFA激活酶，抑铁死亡。ACSL4上游研究不少，但ACSL3怎么被调控、在耐药里扮演什么角色，并不清楚。PHB2以前主要被认为在线粒体里干杂活（维持结构、参与线粒体自噬），有没有胞质里的"兼职功能"？这就是本文切入的窗口。 推理链分步拆解 Step 1：先找耐药里冒头的分子——PHB2是怎么被"捞"出来的 作者先做了一个很经典的耐药模型构建：体外筛选顺铂耐药的AGS细胞，再植回小鼠肚子里形成CDDP-R xenograft，然后RNA-seq对比敏感和耐药肿瘤的转录组。差异基因一堆，怎么聚焦？他们把自家差异基因和NCI-60 CellMiner里基因表达与顺铂GI50的相关性做交集，从中"捞"出PHB2——mRNA在耐药瘤里高表达，而且在NCI-60里表达越高、顺铂越不敏感。紧接着在病人组织里用IHC验证，蛋白水平也是耐药组更高。到这里问题来了：是伴随现象，还是真的驱动耐药？他们用shRNA敲低和过表达做双向因果验证，敲低后耐药细胞重新变敏感，过表达后敏感细胞变耐药；体内也一样，敲低PHB2后顺铂压不住瘤了。`@方法论点评：这里值得学的是"双筛策略"——自己的组学差异 + 公共数据库的药物敏感性关联，两者交集能显著缩小候选范围，避免只看差异基因的假阳性。再看双向表型（敲低+过表达）确认因果关系，是功能研究的金标准。" ![Fig. 1：High PHB2 expression promotes chemotherapy resistance in GC. A,B) Volcano plot (A) of differentially expressed proteins and heatmap (B) of the top 50 proteins in CDDP-R versus CDDP-S AGS xenograft tumors (fold change > 1 or < –1, P < 0.001; n = 4 mice per group). C) Dot plot showing the correlation between expression of selected genes and CDDP sensitivity (GI50 values) across the NCI-60 cell line panel, based on CellMiner analysis. Each dot represents a gene, with size indicating the Spearman correlation coefficient and color corresponding to the statistical significance ( P value). Genes are ranked by correlation strength. PHB2 is highlighted in red, exhibiting a strong negative correlation with CDDP sensitivity. D) IHC staining analysis of PHB2 expression in GC tissues from cisplatin-sensitive (CDDP-S, n = 10) and cisplatin-resistant (CDDP-R, n = 24) patient groups. Representative images are shown. Scale bar, 200 µm. E) Western blot analysis of PHB2 expression in CDDP-S and CDDP-R AGS cells. β-actin was used as control. F,G) Western blot examined PHB2 knockdown efficiency in CDDP-R AGS cells transfected with sh-PHB2 (F), and subsequent MTT assay showed reduced cell viability after 72 hours of CDDP treatment (G). H,I) Overexpression of PHB2 (H) enhanced resistance to CDDP-induced cytotoxicity, as assessed by MTT assay after 72 hours of CDDP treatment (I). J–M) Schematic illustration of the establishment of CDDP-R AGS.sh-scramble and AGS.sh-PHB2 xenograft tumors. BALB/c nude mice bearing CDDP-R AGS-derived xenografts were treated with either 0.9% saline or CDDP (5 mg/kg, intraperitoneally i.p.）) every 2 days for 3 weeks. n = 6 mice per group (J). Representative images (K), tumor weight (L), and growth curves (M) of AGS.sh-scramble and AGS.sh-PHB2 xenografts in BALB/c nude mice. Scale bar, 1 cm. Data represent three independent experiments and are presented as mean ± SD. Quantitative data were normalized to the corresponding sh-scramble control (G,I). One-way (L) or two-way ANOVA followed by Tukey’s multiple comparison (G, I, M). ...